Wherever you work in life sciences, be it in healthcare of pharmaceuticals, data is one word that is on everyone’s lips.
With the falling cost of genome sequencing, it comes as no surprise that there is a growing interest in expanding the availability and accessibility of genomics via consumer testing. Now, Nebula Genomics has entered the market by launching a comprehensive at-home test that analyses the whole genome for just $299.
France has continued to ban people from ordering commercial DNA kits as part of the country’s Bioethics laws. These laws were widely expected to be relaxed and DNA Pass, an advocacy group, are increasing pressure to get these tests legalized.
Our guest contributor Dr Neil Lamb continues his fortnighty Shareable Science Blog. Neil is the Vice President for Educational Outreach at the HudsonAlpha Institute for Biotechnology and Shareable Science will explore how genetics is relevant to people in their everyday lives. Cancer is a disease of the genome, so it stands to reason that genetic […]
The consumer genetic testing platform AncestryDNA will now offer customers genetic testing to understand their risks for a number of health conditions. From Family History to Healthcare Previously, Ancestry has exclusively focused on helping people trace their family history and understand inheritable traits. However, possibly in a bid to keep up with many of their […]
It has been less than a week since the landmark study into the genetics of same-sex sexual behaviour first broke and sparked debate across the twitterverse. There has been much disagreement amongst the scientific and LGBTQ+ communities alike, regarding whether this research should have been conducted at all. Conversely, many have praised the study for […]
The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. We talked to Jill Davies, CEO of GeneMatters. The company provides genetic counselling to patients through a telehealth platform […]
The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. When Ralph Taylor registered his new business, he attempted to declare it as a disadvantaged business enterprise. Businesses headed […]
Consumer genomics company Ancestry has launched the new upgrade to its AncestryDNA experience, Ancestry Communities. Contrary to many commercial DNA sites, Communities promises to specify UK users’ genetic ancestry to a county level.
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
GEDMatch, the DNA database which made news recently for its instrumental role in solving cold criminal cases in the US, has blocked law enforcement from accessing information for the millions of people on its system.
uBiome, a Silicon Valley startup providing tests focussing on the microbiome and its importance to health, is under investigation after an FBI raid on its offices over how it was allegedly billing its customers. The company has received significant criticism recently for handling of the cofounders’ relationship and alleged corner-cutting during its scientific work.
Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.
Genomic compression expert PetaGene has become a NetApp Alliance Partner, the company announced recently, a move set to improve performance and reduce costs for researchers using large datasets within the genomics field.
SOPHiA GENETICS’ Solid Tumor Solution (STS) application was recently granted a CE-IVD designation, a regulatory stamp that a product has satisfied the EU’s in vitro diagnostic device requirements. We spoke to Gioia Althoff, SOPHiA’s Senior Vice President, Genomics Business Area, about the STS application and where SOPHiA is going from here.